Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04982029 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder
A Phase 2 study of Opioid Use Disorder, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT04982029 is a Phase 2 study of Opioid Use Disorder that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 15 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04982029, a Phase 2 study of Opioid Use Disorder, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cannabidiol 100 MG/ML [Epidiolex]
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
Vermont
- Rutland Medical Center - Rutland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-04-14 |
| Est. Completion | 2022-12-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04982029
The ClinicalTrials.gov registry entry for NCT04982029 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (100% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04982029 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Vermont.
Frequently Asked Questions
What is clinical trial NCT04982029 about?
NCT04982029 is a clinical study titled "Cannabidiol on Reward- and Stress-related Neurocognitive Processes in Individuals With Opioid Use Disorder". The purpose of this study is to determine the impact of cannabidiol on reward- and stress-related neurocognitive processes among individuals with opioid use disorder on buprenorphine or methadone treatment.
What is the current status of trial NCT04982029?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-04-14. Estimated completion is 2022-12-02.
What conditions does trial NCT04982029 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT04982029?
The interventions under investigation include: Placebo (DRUG), Cannabidiol 100 MG/ML [Epidiolex] (DRUG).
Who is sponsoring clinical trial NCT04982029?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04982029 being conducted?
This trial has 2 study locations across Massachusetts, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
RECRUITING · Phase 2
-
Remotely Observed Methadone Evaluation II
RECRUITING · Phase 2
-
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
RECRUITING · Phase 2
-
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
RECRUITING · Phase 2
-
Ketamine for Opioid Use Disorder
RECRUITING · Phase 2
-
Brief Digitally-Enhanced Intervention for Reducing Alcohol Use During MOUD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.